Navigation Links
Beckman Coulter Announces Third Quarter 2009 Earnings to be Released on Thursday, October 29, 2009, After Market Closes

ORANGE COUNTY, Calif., Oct. 14 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) announced today it will host a conference call on Thursday, October 29, 2009, at 5:00 p.m. ET to discuss the company's third quarter 2009 results. Earnings will be released after the market closes.


The call may be accessed by dialing (877) 516-3365 or (706) 679-3246 and asking for the Beckman Coulter conference call or reservation number 35948286.

There also will be a live webcast of the call. It will be accessible to all investors through Beckman Coulter's website at When accessing the webcast through the Beckman Coulter site, select "go to IR" under "Investor Relations" and find the call listed under "What's Ahead." The webcast will be archived on both websites for future on-demand replay.

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represent about 78% of the company's 2008 revenue of $3.1 billion. For more information, visit

    Contact:  Cynthia Skoglund                     (714) 961-6320
              Manager, Investor Relations

SOURCE Beckman Coulter, Inc.

SOURCE Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Beckman Coulter Announces the Creation of Beckman Coulter Genomics
2. Upcoming Beckman Coulter Investor Events Second Half of 2009
3. Viles & Beckman, LLC: Stop Your Headache NOT Your Liver
4. Beckman Coulter to Present at the 2009 Goldman Sachs Healthcare Conference
5. Beckman Coulter, Inc. Announces Common Stock Offering
6. Beckman Coulter Pending Acquisition of Olympus Diagnostics Systems Passes Milestone with U.S. Regulatory Approval
7. Beckman Coulter Announces First in Series of Flow Cytometry Product Introductions for 2009
8. Beckman Coulter to Present at Upcoming Healthcare Conferences
9. Beckman Coulter Announces Third Quarter 2008 Results
10. Beckman Coulter to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Beckman Coulter Announces First Quarter 2008 Earnings to be Released on Wednesday, April 30, 2008, Before Market Opens
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... --  MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), a ... an Investigational New Drug Application (IND) with the U.S. ... fully human antibody product HuMab 5B1 as a therapeutic ... the Phase I clinical trial early in 2016. ... planned Phase I trial will evaluate the safety, tolerability ...
(Date:12/1/2015)... 2015  Booth #3506 – Claymount is featuring its full ... of the Radiological Society of North America ... Based in the Netherlands , Claymount is ... (NYSE: VAR ) and is one of the world,s ... state automatic exposure control systems for controlling dose during medical ...
(Date:12/1/2015)... , Dec. 1, 2015  Lexicon Pharmaceuticals, ... that top-line data from its TELECAST Phase ... in treating carcinoid syndrome in cancer patients ... clinical benefit observed in its pivotal TELESTAR ... a companion to TELESTAR primarily to provide ...
Breaking Medicine Technology: